Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of bedtime insulin glargine on endothelial progenitor cells in type 2 diabetes
2006-006573-24Phase 4Terminated
- Sponsor
- Heidelberg University Hospital
- Start
- Feb 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of insulin glargine in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Change in circulating endothelial progenitor cells by FACS and Change in circulating endothelial progenitor cells by in vitro outgrowth. Started Feb 2007; status: terminated.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-006573-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006573-24.